The New Frontier in Longevity Science: Senolytics and Age-Reversal Therapies Introduction Approximately 80% of adults over age 65 worldwide develop at least one chronic condition, from arthritis to dementia. Recent longevity research has identified cellular senescence as a fundamental driver of age-related decline. These
Tag: Ruxolitinib
Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy
A Restrospective Study of Secondary Malignancies in Myelofibrosis Patients Receiving Ruxolitinib Therapy Myelofibrosis (MF) is a chronic, rare, and often fatal type of blood cancer characterized by a progressive replacement of bone marrow with fibrous scar tissue. This type of myeloproliferative neoplasm (MPN) leads to progressive spleen enlargement, systemic symptoms such
